Current Report · Items 2.02, 9.01 · 8-K

InspireMD, Inc

NSPRNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Aug 17, 2026Accepted Aug 17, 2026, 7:05 AM EDTCIK 1433607Accession 0001493152-26-038624

Company context

InspireMD seeks to utilize its proprietary MicroNet ™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

Current securities

NSPRNASDAQ · EQUITY · Current

Historical securities (4)

NSPRWNASDAQ · WARRANT · Historical · closed Dec 3, 2024 NSPR.WSAMEX · WARRANT · Historical · closed Jun 7, 2021 NSPR.WS.BNYSE_AMERICAN · WARRANT · Historical · closed Jun 7, 2021 NSPRZNASDAQ · WARRANT · Historical · closed Mar 14, 2022

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition On August 17, 2026, InspireMD, Inc. (the “Company”) issued a press release announcing its financial and operating results and recent highlights for the three and six months ended June 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Filed exhibits (1)

EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 InspireMD Reports Second Quarter 2026 Financial Results - Company to host investor conference call today, August 17th, at 8:30am EDT - Miami, FL - August 17, 2026 - InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026. Recent Business Highlights: Generated revenue of $1.8 million in the second quarter of 2026, in line with the second quarter of 2025. Robust growth of 21% in international markets was driven by broad-based increases in demand across most countries, offset by the impact of the voluntary recall in the U.S. of the CGuard Prime 135 cm delivery system in May. Announced the appointment of carotid intervention commercial leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing to support the anticipated U.S. re-launch of the CGuard platform. Identified and implemented design changes to the CGuard Prime 135 cm delivery system to address the technical challenges identified following U.S. laun…

Open exhibit ↗